LYRA — Lyra Therapeutics Income Statement
0.000.00%
Last trade - 00:00
- $315.44m
- $212.69m
- $1.56m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 0 | 0.285 | 1.36 | 1.56 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 16.5 | 22.2 | 43.9 | 57.7 | 68.7 |
Operating Profit | -16.5 | -22.2 | -43.6 | -56.3 | -67.1 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -16.3 | -22.1 | -43.5 | -55.3 | -62.6 |
Provision for Income Taxes | |||||
Net Income After Taxes | -16.3 | -22.1 | -43.5 | -55.3 | -62.7 |
Net Income Before Extraordinary Items | |||||
Net Income | -16.3 | -22.1 | -43.5 | -55.3 | -62.7 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -16.3 | -22.2 | -43.5 | -55.3 | -62.7 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -1.32 | -2.59 | -3.35 | -1.8 | -1.24 |
Dividends per Share |